Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Systemic Lupus Erythematosus HELP
Based on 14,843 articles since 2006
||||

These are the 14843 published articles about Lupus Erythematosus, Systemic that originated from Worldwide during 2006-2015.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. 2014

van Vollenhoven, Ronald F / Mosca, Marta / Bertsias, George / Isenberg, David / Kuhn, Annegret / Lerstrøm, Kirsten / Aringer, Martin / Bootsma, Hendrika / Boumpas, Dimitrios / Bruce, Ian N / Cervera, Ricard / Clarke, Ann / Costedoat-Chalumeau, Nathalie / Czirják, László / Derksen, Ronald / Dörner, Thomas / Gordon, Caroline / Graninger, Winfried / Houssiau, Frédéric / Inanc, Murat / Jacobsen, Søren / Jayne, David / Jedryka-Goral, Anna / Levitsky, Adrian / Levy, Roger / Mariette, Xavier / Morand, Eric / Navarra, Sandra / Neumann, Irmgard / Rahman, Anisur / Rovensky, Jozef / Smolen, Josef / Vasconcelos, Carlos / Voskuyl, Alexandre / Voss, Anne / Zakharova, Helena / Zoma, Asad / Schneider, Matthias. ·Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases, Stockholm, Sweden, Karolinska Institutet, , Stockholm, Sweden. · ·Ann Rheum Dis · Pubmed #24739325.

ABSTRACT: The principle of treating-to-target has been successfully applied to many diseases outside rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic targets and pursuing these systematically has led to improved care for patients with these diseases and useful guidance for healthcare providers and administrators. Thus, an initiative to evaluate possible therapeutic targets and develop treat-to-target guidance was believed to be highly appropriate in the management of systemic lupus erythematosus (SLE) patients as well. Specialists in rheumatology, nephrology, dermatology, internal medicine and clinical immunology, and a patient representative, contributed to this initiative. The majority convened on three occasions in 2012-2013. Twelve topics of critical importance were identified and a systematic literature review was performed. The results were condensed and reformulated as recommendations, discussed, modified and voted upon. The finalised bullet points were analysed for degree of agreement among the task force. The Oxford Centre level of evidence (LoE, corresponding to the research questions) and grade of recommendation (GoR) were determined for each recommendation. The 12 systematic literature searches and their summaries led to 11 recommendations. Prominent features of these recommendations are targeting remission, preventing damage and improving quality of life. LoE and GoR of the recommendations were variable but agreement was >0.9 in each case. An extensive research agenda was identified, and four overarching principles were also agreed upon. Treat-to-target-in-SLE (T2T/SLE) recommendations were developed by a large task force of multispecialty experts and a patient representative. It is anticipated that 'treating-to-target' can and will be applicable to the care of patients with SLE.

2 Guideline Overview of lupus nephritis management guidelines and perspective from Asia. 2013

Mok, Chi Chiu / Yap, Desmond Y H / Navarra, Sandra V / Liu, Zhi-Hong / Zhao, Ming-Hui / Lu, Liangjing / Takeuchi, Tsutomu / Avihingsanon, Yingyos / Yu, Xue-Qing / Lapid, Elizabeth A / Lugue-Lizardo, Lenrore R / Sumethkul, Vasant / Shen, Nan / Chen, Shun-le / Chan, Tak Mao / Anonymous6000766. ·Division of Rheumatology, Department of Medicine and Geriatrics, Tuen Mun Hospital, Hong Kong, Hong Kong. · ·Int J Rheum Dis · Pubmed #24382275.

ABSTRACT: Lupus nephritis (LN) is a common and important manifestation of systemic lupus erythematosus (SLE). Evidence suggests higher rates of lupus renal involvement in Asian populations, and maybe more severe nephritis, compared with other racial or ethnic groups. The management of LN has evolved considerably over the past three decades, based on observations from clinical studies that investigated different immunosuppressive agents including corticosteroids, cyclophosphamide, azathioprine, mycophenolic acid, calcineurin inhibitors and novel biologic therapies. This is accompanied by improvements in both the short-term treatment response rate and long-term renal function preservation. Treatment guidelines for LN have recently been issued by rheumatology and nephrology communities in U.S.A. and Europe. In view of the racial difference in disease manifestation and response to therapy, and the substantial disease burden in Asia, a panel of 15 nephrologists and rheumatologists from different Asian regions with extensive experience in lupus nephritis - the Steering Group for the Asian Lupus Nephritis Network (ALNN) - met and discussed the management of lupus nephritis in Asian patients. The group has also reviewed and deliberated on the recently published recommendations from other parts of the world. This manuscript summarizes the discussions by the group and presents consensus views on the clinical management and treatment of adult Asian patients with LN, taking into account both the available evidence and expert opinion in areas where evidence remains to be sought.

3 Guideline SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. 2013

Calvo-Alén, Jaime / Silva-Fernández, Lucía / Úcar-Angulo, Eduardo / Pego-Reigosa, José María / Olivé, Alejandro / Martínez-Fernández, Carmen / Martínez-Taboada, Víctor / Luis Marenco, José / Loza, Estíbaliz / López-Longo, Javier / Gómez-Reino, Juan Jesús / Galindo-Izquierdo, María / Fernández-Nebro, Antonio / Cuadrado, María José / Aguirre-Zamorano, María Ángeles / Zea-Mendoza, Antonio / Rúa-Figueroa, Iñigo / Anonymous4840755. ·Sección de Reumatología, Hospital Universitario Sierrallana, Torrelavega, Cantabria, Spain. · ·Reumatol Clin · Pubmed #23871156.

ABSTRACT: OBJECTIVE: To provide a reference to rheumatologists and other physicians involved in the treatment of systemic lupus erythematosus (SLE) who are using, or about to use biologic therapies. METHODS: Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and degree of recommendation were classified according to a model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through a Delphi technique. RESULTS: We have produced recommendations on the use of belimumab, the only biological agent with approved indications for SLE, and other biological agents without an indication for SLE. The objective of treatment is to achieve a complete clinical response, taken as the absence of perceived or evident disease activity. Nuances regarding the use of biologic therapies in SLE were reviewed as well, such as the evaluation that should be performed prior to administration and the follow up of patients undergoing these therapies. CONCLUSIONS: We present the SER recommendations for the use of biological therapies in patients with SLE.

4 Guideline [Statement on the use of mycophenolate mofetil for systemic lupus erythematosus]. 2013

Aringer, M / Fischer-Betz, R / Hiepe, F / Anonymous3750755 / Anonymous3760755. ·Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland. martin.aringer@uniklinikum-dresden.de · ·Z Rheumatol · Pubmed #23756593.

ABSTRACT: Mycophenolate mofetil (MMF) is among the few immunosuppressive drugs with sufficient data from controlled studies on the therapy of systemic lupus erythematosus (SLE). In the light of results from recently published randomized controlled trials on the effectiveness of MMF in the treatment of lupus nephritis, it has become necessary to revise the statement of the Germany Society of Rheumatology on the use of MMF for SLE. In the induction therapy of lupus nephritis MMF has been shown to be equivalent in effectiveness to i.v. cyclophosphamide and superior to azathioprine in the maintenance phase. Cyclophosphamide is inferior to MMF and probably also to azathioprine as maintenance therapy and should therefore, not be considered for this purpose and also because of its toxicity. For other organ manifestations MMF also constitutes an alternative when approved immunosuppressants are not able to control the disease and glucocorticoids cannot be reduced to 7.5 mg prednisolone daily equivalents or less.

5 Guideline [Recommendations on the use of belimumab in systemic lupus erythematosus. GEAS-SEMI Clinical Practice Guide]. 2013

Ramos-Casals, M / Ruiz-Irastorza, G / Jiménez-Alonso, J / Khamashta, M A / Anonymous680742. ·Servicio de Enfermedades Autoinmunes, Laboratorio de Enfermedades Autoinmunes Josep Font, IDIBAPS, Hospital Clínic, Barcelona, España. mramos@clinic.ub.es · ·Rev Clin Esp (Barc) · Pubmed #23266125.

ABSTRACT: Biological therapies are based on the administration of various types of synthetic molecules related to the immune response. Their use has spread in recent years to the field of systemic autoimmune diseases, particularly to systemic lupus erythematosus (SLE). Until 2011, these diseases were not included in the therapeutic indications approved by international regulatory agencies. Therefore, the use of biological therapies was restricted to clinical trials and to compassionate use for cases refractory to standard treatments (off-label use), which require the approval of the Health Ministry. In 2011, belimumab, a human monoclonal antibody that specifically binds to the soluble form of the protein human B lymphocyte stimulator BlyS, was approved for use in patients with SLE. Because the clinical information on the use of this new drug in patients with SLE has only been obtained from the results of randomized trials, the Study Group of Autoimmune Diseases (GEAS) of the Spanish Society of Internal Medicine (SEMI) has developed therapeutic guidelines. These guidelines are based on the current scientific evidence on the use of belimumab in SLE patients in the clinical practice.

6 Guideline Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. 2012

Bertsias, George K / Tektonidou, Maria / Amoura, Zahir / Aringer, Martin / Bajema, Ingeborg / Berden, Jo H M / Boletis, John / Cervera, Ricard / Dörner, Thomas / Doria, Andrea / Ferrario, Franco / Floege, Jürgen / Houssiau, Frederic A / Ioannidis, John P A / Isenberg, David A / Kallenberg, Cees G M / Lightstone, Liz / Marks, Stephen D / Martini, Alberto / Moroni, Gabriela / Neumann, Irmgard / Praga, Manuel / Schneider, Matthias / Starra, Argyre / Tesar, Vladimir / Vasconcelos, Carlos / van Vollenhoven, Ronald F / Zakharova, Helena / Haubitz, Marion / Gordon, Caroline / Jayne, David / Boumpas, Dimitrios T / Anonymous360729. ·Department of Medicine, Rheumatology, Clinical Immunology and Allergy, University of Crete, Iraklion, Greece. · ·Ann Rheum Dis · Pubmed #22851469.

ABSTRACT: OBJECTIVES: To develop recommendations for the management of adult and paediatric lupus nephritis (LN). METHODS: The available evidence was systematically reviewed using the PubMed database. A modified Delphi method was used to compile questions, elicit expert opinions and reach consensus. RESULTS: Immunosuppressive treatment should be guided by renal biopsy, and aiming for complete renal response (proteinuria <0.5 g/24 h with normal or near-normal renal function). Hydroxychloroquine is recommended for all patients with LN. Because of a more favourable efficacy/toxicity ratio, as initial treatment for patients with class III-IV(A) or (A/C) (±V) LN according to the International Society of Nephrology/Renal Pathology Society 2003 classification, mycophenolic acid (MPA) or low-dose intravenous cyclophosphamide (CY) in combination with glucocorticoids is recommended. In patients with adverse clinical or histological features, CY can be prescribed at higher doses, while azathioprine is an alternative for milder cases. For pure class V LN with nephrotic-range proteinuria, MPA in combination with oral glucocorticoids is recommended as initial treatment. In patients improving after initial treatment, subsequent immunosuppression with MPA or azathioprine is recommended for at least 3 years; in such cases, initial treatment with MPA should be followed by MPA. For MPA or CY failures, switching to the other agent, or to rituximab, is the suggested course of action. In anticipation of pregnancy, patients should be switched to appropriate medications without reducing the intensity of treatment. There is no evidence to suggest that management of LN should differ in children versus adults. CONCLUSIONS: Recommendations for the management of LN were developed using an evidence-based approach followed by expert consensus.

7 Guideline American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. 2012

Hahn, Bevra H / McMahon, Maureen A / Wilkinson, Alan / Wallace, W Dean / Daikh, David I / Fitzgerald, John D / Karpouzas, George A / Merrill, Joan T / Wallace, Daniel J / Yazdany, Jinoos / Ramsey-Goldman, Rosalind / Singh, Karandeep / Khalighi, Mazdak / Choi, Soo-In / Gogia, Maneesh / Kafaja, Suzanne / Kamgar, Mohammad / Lau, Christine / Martin, William J / Parikh, Sefali / Peng, Justin / Rastogi, Anjay / Chen, Weiling / Grossman, Jennifer M / Anonymous4360716. ·School of Medicine, University of California-Los Angeles, CA 90095-1670, USA. bhahn@mednet.ucla.edu · ·Arthritis Care Res (Hoboken) · Pubmed #22556106.

ABSTRACT: -- No abstract --

8 Guideline [Diagnosis and treatment of lupus nephritis]. 2012

Ruiz-Irastorza, G / Espinosa, G / Frutos, M A / Jiménez Alonso, J / Praga, M / Pallarés, L / Rivera, F / Robles Marhuenda, Á / Segarra, A / Quereda, C / Anonymous920713 / Anonymous930713. ·Unidad de Investigación de Enfermedades Autoinmunes, Servicio de Medicina Interna, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Bizkaia, España. r.irastorza@euskaltel.net · ·Rev Clin Esp · Pubmed #22361331.

ABSTRACT: -- No abstract --

9 Guideline Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). 2012

Ruiz Irastorza, Guillermo / Espinosa, Gerard / Frutos, Miguel A / Jiménez Alonso, Juan / Praga, Manuel / Pallarés, Lucio / Rivera, Francisco / Robles Marhuenda, Angel / Segarra, Alfons / Quereda, Carlos / Anonymous3680709 / Anonymous3690709. ·Unidad de Investigación de Enfermedades Autoinmunes, Servicio de Medicina Interna. Hospital Universitario Cruces, UPV/EHU, Barakaldo, Bizkaia, Spain. r.irastorza@euskaltel.net · ·Nefrologia · Pubmed #22293933.

ABSTRACT: -- No abstract --

10 Guideline Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. 2012

Aringer, M / Burkhardt, H / Burmester, G R / Fischer-Betz, R / Fleck, M / Graninger, W / Hiepe, F / Jacobi, A M / Kötter, I / Lakomek, H J / Lorenz, H M / Manger, B / Schett, G / Schmidt, R E / Schneider, M / Schulze-Koops, H / Smolen, J S / Specker, C / Stoll, T / Strangfeld, A / Tony, H P / Villiger, P M / Voll, R / Witte, T / Dörner, T. ·Rheumatology, Medicine III, University Medical Center TU Dresden, Germany. martin.aringer@uniklinikum-dresden.de · ·Lupus · Pubmed #22072024.

ABSTRACT: Systemic lupus erythematosus (SLE) can be a severe and potentially life-threatening disease that often represents a therapeutic challenge because of its heterogeneous organ manifestations. Only glucocorticoids, chloroquine and hydroxychloroquine, azathioprine, cyclophosphamide and very recently belimumab have been approved for SLE therapy in Germany, Austria and Switzerland. Dependence on glucocorticoids and resistance to the approved therapeutic agents, as well as substantial toxicity, are frequent. Therefore, treatment considerations will include 'off-label' use of medication approved for other indications. In this consensus approach, an effort has been undertaken to delineate the limits of the current evidence on therapeutic options for SLE organ disease, and to agree on common practice. This has been based on the best available evidence obtained by a rigorous literature review and the authors' own experience with available drugs derived under very similar health care conditions. Preparation of this consensus document included an initial meeting to agree upon the core agenda, a systematic literature review with subsequent formulation of a consensus and determination of the evidence level followed by collecting the level of agreement from the panel members. In addition to overarching principles, the panel have focused on the treatment of major SLE organ manifestations (lupus nephritis, arthritis, lung disease, neuropsychiatric and haematological manifestations, antiphospholipid syndrome and serositis). This consensus report is intended to support clinicians involved in the care of patients with difficult courses of SLE not responding to standard therapies by providing up-to-date information on the best available evidence.

11 Guideline [SGI-PS-CMA evidence-based recommendations for the diagnosis and management of juvenile systemic lupus erythematosus]. 2011

Anonymous60702 / Anonymous70702 / Anonymous80702. · ·Zhonghua Er Ke Za Zhi · Pubmed #22088179.

ABSTRACT: -- No abstract --

12 Guideline [Evidence-based guidelines for diagnosis and treatment of common renal diseases in children (for trial) (VI): guidelines for the diagnosis and treatment of lupus nephritis]. 2010

Anonymous140674. · ·Zhonghua Er Ke Za Zhi · Pubmed #21092530.

ABSTRACT: -- No abstract --

13 Guideline European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. 2010

Mosca, M / Tani, C / Aringer, M / Bombardieri, S / Boumpas, D / Brey, R / Cervera, R / Doria, A / Jayne, D / Khamashta, M A / Kuhn, A / Gordon, C / Petri, M / Rekvig, O P / Schneider, M / Sherer, Y / Shoenfeld, Y / Smolen, J S / Talarico, R / Tincani, A / van Vollenhoven, R F / Ward, M M / Werth, V P / Carmona, L. ·Correspondence to Dr Marta Mosca, University of Pisa, via Roma 67, Ospedale S. Chiara, Pisa, 56126, Italy. marta.mosca@int.med.unipi.it · ·Ann Rheum Dis · Pubmed #19892750.

ABSTRACT: OBJECTIVES: To develop recommendations for monitoring patients with systemic lupus erythematosus (SLE) in clinical practice and observational studies and to develop a standardised core set of variables to monitor SLE. METHODS: We followed the European League Against Rheumatism (EULAR) standardised procedures for guideline development. The following techniques were applied: nominal groups, Delphi surveys for prioritisation, small group discussion, systematic literature review and two Delphi rounds to obtain agreement. The panel included rheumatologists, internists, dermatologists, a nephrologist and an expert related to national research agencies. The level of evidence and grading of recommendations were determined according to the Levels of Evidence and Grades of Recommendations of the Oxford Centre for Evidence-Based Medicine. RESULTS: A total of 10 recommendations have been developed, covering the following aspects: patient assessment, cardiovascular risk factors, other risk factors (osteoporosis, cancer), infection risk (screening, vaccination, monitoring), frequency of assessments, laboratory tests, mucocutaneous involvement, kidney monitoring, neuropsychological manifestations and ophthalmology assessment. A 'core set' of minimal variables for the assessment and monitoring of patients with SLE in clinical practice was developed that included some of the recommendations. In addition to the recommendations, indications for specific organ assessments that were viewed as part of good clinical practice were discussed and included in the flow chart. CONCLUSIONS: A set of recommendations for monitoring patients with SLE in routine clinical practice has been developed. The use of a standardised core set to monitor patients with SLE should facilitate clinical practice, as well as the quality control of care for patients with SLE, and the collection and comparison of data in observational studies.

14 Guideline EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints. 2009

Bertsias, G K / Ioannidis, J P A / Boletis, J / Bombardieri, S / Cervera, R / Dostal, C / Font, J / Gilboe, I M / Houssiau, F / Huizinga, T / Isenberg, D / Kallenberg, C G M / Khamashta, M / Piette, J C / Schneider, M / Smolen, J / Sturfelt, G / Tincani, A / van Vollenhoven, R / Boumpas, D T / Gordon, C. ·Internal Medicine, and Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Greece. · ·Ann Rheum Dis · Pubmed #18434449.

ABSTRACT: OBJECTIVE: To assess available evidence on the use of end-points (outcome measures) in clinical trials in systemic lupus erythematosus (SLE), as a part of the development of evidence-based recommendations for points to consider in clinical trials in SLE. METHODS: The European League Against Rheumatism (EULAR) Task Force on SLE comprised 19 specialists, a clinical epidemiologist and a research fellow. Key questions addressing the evidence for clinical trial end-points in SLE were compiled using the Delphi technique. A systematic search of the PubMed and Cochrane Library databases was performed using McMaster/Hedges clinical query strategies and an array of relevant terms. Evidence was categorised based on sample size and type of design, and the categories of available evidence were identified for each recommendation. The strength of recommendation was assessed based on the category of available evidence and agreement on the statements was measured across the 19 specialists. RESULTS: Eight questions were generated regarding end-points for clinical trials. The evidence to support each proposition was evaluated. The literature review revealed that most outcome measures used in phase 2/3 trials in SLE have not been formally validated in clinical trials, although some indirect validation has been undertaken. CONCLUSION: This systematic literature review forms the evidence base considered in the development of the EULAR recommendations for end-points in clinical trials in SLE.

15 Guideline EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. 2009

Gordon, C / Bertsias, G / Ioannidis, J P A / Boletis, J / Bombardieri, S / Cervera, R / Dostál, C / Font, J / Gilboe, I-M / Houssiau, F / Huizinga, T W J / Isenberg, D / Kallenberg, C G M / Khamashta, M A / Piette, J-C / Schneider, M / Smolen, J S / Sturfelt, G / Tincani, A / Van Vollenhoven, R / Boumpas, D T. ·Rheumatology Research Group, Division of Immunity and Infection, The University of Birmingham, Birmingham, UK. p.c.gordon@bham.ac.uk · ·Ann Rheum Dis · Pubmed #18388158.

ABSTRACT: OBJECTIVE: Systemic lupus erythematosus (SLE) is a complex multi-organ disease, characterised by relapses and remissions. DESIGN: ng a high-quality randomised controlled trial poses many challenges. We have developed evidenced-based recommendations for points to consider in conducting clinical trials in patients with SLE. METHODS: The EULAR Task Force on SLE comprised 19 specialists and a clinical epidemiologist. Initially, the evidence for clinical trial end-points in SLE was evaluated and this has been reported separately. A consensus approach was developed by the SLE Task Force in formulating recommendations for points to consider when conducting clinical trials in SLE. RESULTS: The literature review revealed that most outcome measures used in phase 2/3 trials in SLE have not actually been validated in clinical trials, although other forms of validation have been undertaken. The final recommendations for points to consider for conducting clinical trials in SLE address the following areas: study design, eligibility criteria, outcome measures including adverse events, concomitant therapies for SLE and its complications. CONCLUSIONS: Recommendations for points to consider when conducting clinical trials in SLE were developed using an evidence-based approach followed by expert consensus. The recommendations should be disseminated, implemented and then reviewed in detail and revised using an evidence-based approach in about 5 years, by which time there will be further evidence to consider from current clinical trials.

16 Guideline Rituximab (MabThera) therapy and safety management. Clinical tool guide. 2008

Pham, Thao / Fautrel, Bruno / Gottenberg, Jacques-Eric / Goupille, Philippe / Hachulla, Eric / Masson, Charles / Morel, Jacques / Mouthon, Luc / Saraux, Alain / Schaeverbeke, Thierry / Wendling, Daniel / Mariette, Xavier / Sibilia, ? / Anonymous7070614. · ·Joint Bone Spine · Pubmed #18708020.

ABSTRACT: -- No abstract --

17 Guideline EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. 2008

Bertsias, G / Ioannidis, J P A / Boletis, J / Bombardieri, S / Cervera, R / Dostal, C / Font, J / Gilboe, I M / Houssiau, F / Huizinga, T / Isenberg, D / Kallenberg, C G M / Khamashta, M / Piette, J C / Schneider, M / Smolen, J / Sturfelt, G / Tincani, A / van Vollenhoven, R / Gordon, C / Boumpas, D T / Anonymous4350601. ·Department of Internal Medicine, University of Crete School of Medicine, 71003, Heraklion, Greece. · ·Ann Rheum Dis · Pubmed #17504841.

ABSTRACT: OBJECTIVE: Systemic lupus erythematosus (SLE) is a complex disease with variable presentations, course and prognosis. We sought to develop evidence-based recommendations addressing the major issues in the management of SLE. METHODS: The EULAR Task Force on SLE comprised 19 specialists and a clinical epidemiologist. Key questions for the management of SLE were compiled using the Delphi technique. A systematic search of PubMed and Cochrane Library Reports was performed using McMaster/Hedges clinical queries' strategies for questions related to the diagnosis, prognosis, monitoring and treatment of SLE. For neuropsychiatric, pregnancy and antiphospholipid syndrome questions, the search was conducted using an array of relevant terms. Evidence was categorised based on sample size and type of design, and the categories of available evidence were identified for each recommendation. The strength of recommendation was assessed based on the category of available evidence, and agreement on the statements was measured across the 19 specialists. RESULTS: Twelve questions were generated regarding the prognosis, diagnosis, monitoring and treatment of SLE, including neuropsychiatric SLE, pregnancy, the antiphospholipid syndrome and lupus nephritis. The evidence to support each proposition was evaluated and scored. After discussion and votes, the final recommendations were presented using brief statements. The average agreement among experts was 8.8 out of 10. CONCLUSION: Recommendations for the management of SLE were developed using an evidence-based approach followed by expert consensus with high level of agreement among the experts.

18 Guideline [Interdisciplinary consensus to management of lupus nephritis in Germany]. 2007

de Groot, K. ·Medizinische Klinik III, Klinikum Offenbach GmbH, Starkenburgring 66, 63069, Offenbach/Main, Germany. kirsten@de-groot.de ·Z Rheumatol · Pubmed #17965864.

ABSTRACT: In October 2006 a German ad hoc committee consisting of rheumatologists and nephrologists developed a consensus statement on the current practice in the management of lupus nephritis. The published results are summarized.

19 Guideline [Treating lupus nephritis: guideline from the Italian Society of Nephrology]. 2007

Stratta, P / Canavese, C / Lupo, A / Pozzi, C / Passerini, P / Cagnoli, L / Manno, C / Strippoli, G F M / Anonymous7210580. ·Italian Society of Nephrology - Italy. · ·G Ital Nefrol · Pubmed #17347955.

ABSTRACT: BACKGROUND: The current 3rd edition of the Italian Society of Nephrology guidelines has been drawn up to summarize evidence of key intervention issues on the basis of systematic reviews (SR) of randomized trials (RCT) or RCT data only. In the present guideline, evidence of lupus nephritis (LN) treatment is presented. METHODS: SR of RCT and RCT on different therapeutic options for LN were identified referring to a Cochrane Library and Renal Health Library search (2005 update). RESULTS: One SR of 25 RCT and 6 further RCT were available to address this issue. Methodological quality of available RCT was suboptimal according to current methodological standards. In LN patients, combining cyclophosphamide (CyA) and steroids as induction therapy results in a reduced risk of serum creatinine doubling compared to steroids alone, although there is no evidence of significant survival advantage and risk of ovarian failure was demonstrated (evidence from SR). The association of azathioprine (Aza) and steroids significantly reduces the risk of all-cause mortality compared to steroids alone (evidence from SR). No significant survival advantages from the association of plasma exchange and CyA or Aza are proven (evidence from SR). No significant differences on renal and survival endpoints are demonstrated with different dosing of CyA (evidence from RCT). CONCLUSION: In LN patients available evidence supports the hypothesis that immunosuppressive agents reduce the risk of all-cause mortality and the risk of progressive renal disease. Further studies are necessary to test new immunosuppressive agents such as mycophenolate mofetil in severe LN patients.

20 Guideline [Systemic lupus erythematosus: cutaneous/articular injuries]. 2006

Anonymous5380575. ·Sociedade Brasileira de Reumatologia ·Rev Assoc Med Bras · Pubmed #17242769.

ABSTRACT: -- No abstract --

21 Editorial Driving forces of inflammatory diseases: Th9 in allergic rhinitis and estrogen in SLE. 2015

Palaga, Tanapat. ·Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand 10330. ·Asian Pac J Allergy Immunol · Pubmed #26708388.

ABSTRACT: -- No abstract --

22 Editorial Screening for Pulmonary Hypertension in Antiphospholipid Antibody Positive Lupus Erythematosus. 2015

Chogle, Arun R. · ·J Assoc Physicians India · Pubmed #26591163.

ABSTRACT: -- No abstract --

23 Editorial The Challenges of Adolescence, Mood Disorders, and Chronic Illness. 2015

Klein-Gitelman, Marisa S / Curran, Megan L. ·Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Division of Rheumatology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois. Electronic address: Klein-gitelman@northwestern.edu. · Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Division of Rheumatology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois. ·J Pediatr · Pubmed #26421489.

ABSTRACT: -- No abstract --

24 Editorial Cord Blood Samples: A Less Explored Tool in Early Diagnosis of Neonatal Cardiovascular Disease. 2015

Sliwa, Karen / Hilfiker-Kleiner, Denise. ·Hatter Institute for Cardiovascular Research in Africa & IDM, Inter-Cape Heart Group, Medical Research Council South Africa, Department of Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: Karen.Sliwa-Hahnle@uct.ac.za. · Department of Cardiology and Angiology, Medical School Hannover, Hannover, Germany. ·J Am Coll Cardiol · Pubmed #26293765.

ABSTRACT: -- No abstract --

25 Editorial Pregnancy in Women With Systemic Lupus Erythematosus: Messages for the Clinician. 2015

Hahn, Bevra H. · ·Ann Intern Med · Pubmed #26099038.

ABSTRACT: -- No abstract --

Next